Fan mail from Bob M.: "Your job is to write biased articles. You comment on stocks because it's fun. You have zero background in biotechnology, you have no medical or scientific credentials. Talk about leading lemmings over the cliff. Why would anyone believe a word that you say? TheStreet is certainly getting what they payed
Lastly, Adrian S. emails, "Really enjoy your articles. I sent you one email on this already and surprised you haven't jumped in on this yet. Labopharm (DDSS) looks to have a lot of promise at this juncture, having just launched Oleptro in the U.S. with their partner Angelini. With Canadian Oleptro approval and tramadol/acetaminophen combo approval in Europe by year's end I think it makes for an exciting near term story. What are your thoughts?" Not so fast, Adrian. Oleptro's U.S. launch isn't going well, even slower than expectations, which weren't all that high to begin with. And while the positive opinion from European regulators for the tramadol/acetaminophen combo is encouraging, launch is probably a year away and may be met with the same indifference there as tramadol. Labopharm is still a show-me stock. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.